Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
Sequential treatment with endocrine or chemotherapy is generally used in the treatment of estrogen receptor (ER)-positive recurrent breast cancer. To date, few studies have investigated the effect of long-term endocrine therapy on the response to subsequent chemotherapy in ER-positive breast cancer....
Guardado en:
Autores principales: | Takayuki Watanabe, Takaaki Oba, Keiji Tanimoto, Tomohiro Shibata, Shinobu Kamijo, Ken-Ichi Ito |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5362605a848c460bb25cd70fbbc06aa8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen.
por: Jennifer M Bordeaux, et al.
Publicado: (2012) -
How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?
por: Katherine D. Crew, et al.
Publicado: (2017) -
Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
por: Rangel N, et al.
Publicado: (2017) -
The antiestrogens tamoxifen and fulvestrant abolish estrogenic impacts of 17α-ethinylestradiol on male calling behavior of Xenopus laevis.
por: Frauke Hoffmann, et al.
Publicado: (2012) -
Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.
por: Li Yin, et al.
Publicado: (2014)